Research programme: LRRK2 inhibitors - NovartisAlternative Names: Research programme: leucine rich repeat kinase 2 inhibitors - Novartis
Latest Information Update: 16 Jul 2016
At a glance
- Originator Novartis
- Mechanism of Action LRRK2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in Switzerland
- 21 Oct 2009 Early research in Parkinson's disease in Switzerland (unspecified route)